Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
NeuroSense Therapeutics
NRSN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$1.40
0.05
3.70%
Last update: 7:41 AM
15 minutes delayed
Get Report
Comment
NeuroSense Therapeutics (NRSN) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for NeuroSense Therapeutics (NASDAQ:NRSN) Stock
NeuroSense Therapeutics Stock (NASDAQ: NRSN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, August 30, 2024
NeuroSense Therapeutics Receives Receipt Of N...
Benzinga Newsdesk
Wednesday, August 28, 2024
EXCLUSIVE: NeuroSense Therapeutics Tells Benz...
Benzinga Newsdesk
EXCLUSIVE: NeuroSense Therapeutics Tells Benz...
Benzinga Newsdesk
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
Vandana Singh
Friday, August 16, 2024
NeuroSense Therapeutics Entered Into Capital ...
Benzinga Newsdesk
Wednesday, August 07, 2024
NeuroSense Therapeutics Announces $600K Priva...
Benzinga Newsdesk
Thursday, August 01, 2024
NeuroSense Therapeutics Announces Biomarker D...
Benzinga Newsdesk
Tuesday, July 09, 2024
NeuroSense Highlights PARADIGM Clinical Trial...
Benzinga Newsdesk
Monday, July 01, 2024
NeuroSense shares are trading higher after th...
Benzinga Newsdesk
NeuroSense Reports Results From 12-Month Anal...
Benzinga Newsdesk
Friday, June 28, 2024
NeuroSense Therapeutics Receives Notice Of Al...
Benzinga Newsdesk
Monday, June 24, 2024
NeuroSense Therapeutics Q1 EPS $(0.35) Misses...
Benzinga Newsdesk
Friday, June 21, 2024
NeuroSense Receives Nasdaq Delisting Notice
Benzinga Newsdesk
Tuesday, May 14, 2024
NeuroSense Therapeutics Partners With PhaseV ...
Benzinga Newsdesk
Tuesday, May 07, 2024
NeuroSense Announces New Data Analysis From P...
Benzinga Newsdesk
Monday, April 22, 2024
NeuroSense shares are trading higher after th...
Benzinga Newsdesk
NeuroSense and Genetika+ Initiate Precision M...
Benzinga Newsdesk
Thursday, April 18, 2024
NeuroSense Presents Data Validating Phase 2b ...
Benzinga Newsdesk
Friday, April 12, 2024
NeuroSense To Present PARADIGM Data At Americ...
Benzinga Newsdesk
Thursday, April 11, 2024
Reported Earlier, NeuroSense Therapeutics Pri...
Benzinga Newsdesk
Tuesday, April 09, 2024
NeuroSense Collaborates With Lonza To Identif...
Benzinga Newsdesk
Friday, April 05, 2024
NeuroSense Therapeutics Q4 EPS $(0.16) Beats ...
Benzinga Newsdesk
NeuroSense FY23 EPS $(0.83) Beats $(0.85) Est...
Benzinga Newsdesk
Wednesday, February 21, 2024
NeuroSense Reports Results From Its ALS Phase...
Benzinga Newsdesk
Wednesday, February 07, 2024
NeuroSense Regains Nasdaq Compliance
Benzinga Newsdesk
Monday, January 29, 2024
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Meg Flippin
-
Sponsored
Tuesday, January 09, 2024
NeuroSense Reviews 2023 Achievements; Provide...
Benzinga Newsdesk
Wednesday, December 27, 2023
NeuroSense Reveals Receipt Of Nasdaq Notice R...
Benzinga Newsdesk
Thursday, December 14, 2023
NeuroSense Therapeutics shares are trading hi...
Benzinga Newsdesk
NeuroSense Reports Efficacy Data From Further...
Benzinga Newsdesk
Wednesday, December 06, 2023
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
US Stocks Higher; Private Payrolls Rise By 103,000 In November
Lisa Levin
Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Lisa Levin
Tuesday, December 05, 2023
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
NeuroSense Therapeutics shares are trading lo...
Benzinga Newsdesk
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Lisa Levin
NeuroSense Announces It Met Its Primary Safet...
Benzinga Newsdesk
Monday, December 04, 2023
NeuroSense Will Report New Data From Randomiz...
Bill Haddad
Tuesday, November 28, 2023
NeuroSense 9-Month EPS $(0.67) Vs $(0.80) YoY
Benzinga Newsdesk
Monday, November 13, 2023
NeuroSense Receives U.S. FDA Confirmation Of ...
Benzinga Newsdesk
Wednesday, October 18, 2023
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC
Faith Ashmore
-
Sponsored
Tuesday, October 17, 2023
Neurosense Therapeutics Ltd Phase 2 Alzheimer...
Benzinga Newsdesk
Wednesday, October 04, 2023
NeuroSense's PrimeC Demonstrates Outstanding ...
Benzinga Newsdesk
Monday, October 02, 2023
NeuroSense Ends Its At-The-market Equity Offe...
Benzinga Newsdesk
Friday, September 29, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Wednesday, September 20, 2023
European Medicines Agency Grants NeuroSense S...
Benzinga Newsdesk
Tuesday, September 19, 2023
NeuroSense Granted Patents In Europe, Japan, ...
Benzinga Newsdesk
Monday, September 11, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Wednesday, August 16, 2023
NeuroSense Therapeutics H1 EPS $(0.77), Down ...
Benzinga Newsdesk
Monday, July 17, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
Benzinga Insights
Show More
